Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Abstract: A polymer-ceramic composite membrane and methods of making the same. The composite membrane includes a polymer scaffold and a ceramic nanoparticle disposed within the polymer scaffold.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle dystrophy (DM1).

Abstract: An electrochemical cell and a method of manufacturing the electrochemical cell are provided. The method includes: spraying a precursor solution on an anode, the precursor solution including a metal salt dissolved in a solvent and the anode being at a temperature of 250° C. or greater; reacting the metal salt on the anode to form a buffer layer; and attaching a solid-state electrolyte to the buffer layer.

Abstract: A method of operating a fuel cell system (100) comprising a fuel cell stack (110) and a closed loop water cooling circuit for direct injection of cooling water into the stack (110), the method comprising: measuring an operational parameter of the fuel cell system (100) over a time period; adding an amount of water to the closed loop cooling circuit from the total amount of water generated during operation of the fuel cell stack (110) over the time period; and removing the amount of water from the closed loop cooling circuit generated during operation of the fuel cell stack (110) over the time period is automatically determined by the fuel cell system (100) as a function of the operational parameter.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle dystrophy (DM1).

Abstract: A fluid flow plate for an electrochemical fuel cell assembly comprises a first plurality of fluid flow channels extending across an area of the flow plate to define a flow field of the fluid flow plate. An array of first fluid transfer points is disposed along an edge of the flow field for communicating fluid into or out of the fluid flow channels. A gallery has a first peripheral edge portion bounded by the array of first fluid transfer points and at least two second peripheral edge portions each bounded by an array of second fluid transfer points disposed along fluid access edges of the fluid flow plate. The at least two second peripheral edge portions are disposed at oblique angles to the first peripheral edge portion such that the total length of the any of second fluid transfer points is at least as long as, and preferably longer than, the length of the array of first fluid transfer points.

Abstract: Aspects of duct systems for use with fuel cells and methods of using the same are disclosed. According to an aspect of the disclosure, a duct system (10) for cooling fuel cells (12) via a coolant fluid includes a housing (100); a cooling chamber (112); an inlet port (120) configured to receive the coolant into the system; an exhaust port (130) configured to expel the coolant from the system; and a means for moving the coolant into, through, and out of the system.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle dystrophy (DM1).

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle dystrophy (DM1).

Abstract: A coolant storage tank (1) for storing coolant in a fuel cell system (2), the coolant storage tank comprising a plurality of individually controllable heater elements (7, 8a, 8b). A coolant storage tank comprising a first heater element (7) located at a base of the coolant storage tank and a second heater element (8a) is also disclosed. A coolant storage tank comprising a first coolant storage compartment (50) in fluid communication with a second coolant storage compartment (51), the first coolant storage compartment including at least a first heater element (54) and wherein the second coolant storage compartment is unheated is also disclosed. A method of melting frozen coolant in a coolant storage tank is also disclosed.

Abstract: The invention relates to bipolar plates for electrochemical fuel cell assemblies, and in particular to configurations of bipolar plates allowing for multiple fluid flow channels for the passage of anode, cathode and coolant fluids.

Abstract: A fluid flow plate having first and second fluid flow channels on a fluid flow plate with an active area of fluid flow fields having one or more arrays of fluid transfer points (301, 302, 303) disposed along an edge of the flow field for communicating fluid into or out of flow channels. A first and second distribution gallery (15, 16, 21) with peripheral edge portions bounded by the arrays including at least one pair of inlets in external edges of the fluid flow plate and wherein the first fluid distribution gallery is shaped such that the combined lengths of the first-gallery second peripheral edge portions are longer than the first-gallery first peripheral edge portion, and wherein the internal edges of the flow plate comprise edges of a hole, aperture, or port passing through the flow plate, and the external edges of the flow plate comprise an outer peripheral edge of the plate. The edges each may comprise a castellated structure (31, 32, 34).

Abstract: A lithium ion conductor includes a compound of Formula 1: Li7-a*?-(b-4)*?-xMa?La3Zr2-?Mb?O12-x-?XxN???Formula 1 wherein in Formula 1, Ma is a cationic element having a valence of a, Mb is a cationic element having a valence of b, and X is an anion having a valence of ?1, wherein, when Ma comprises H, 0???5, otherwise 0???0.75, and wherein 0???1.5, 0?x?1.5, (a*?+(b?4)?+x)>0, and 0<??6.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle dystrophy (DM1).

Abstract: A component for a lithium battery including a first layer including a lithium garnet having a porosity of 0 percent to less than 25 percent, based on a total volume of the first layer; and a second layer on the first layer and having a porosity of 25 percent to 80 percent, based on a total volume of the second layer, wherein the second layer is on the first layer and the second layer has a composition that is different from a composition of the first layer.

Abstract: The invention provides a catalyst and a method for making the catalyst. The catalyst comprises a porous carbon composite impregnated with a salt. The catalyst comprises a porous carbon composite impregnated with a salt.

Abstract: A method is implemented by a processor of a computing device for generating an output match action table (MAT) or output MAT template from an input MAT template. The input MAT template is transformed through successive updates of symbolic actions using policy rules into the output MAT or output MAT template. The method includes selecting a first MAT row from the input MAT template and selecting a first action field from the first MAT row. A check is made whether the first action field includes a first symbolic action. The first symbolic action is looked up to determine whether a first policy rule has been defined for the first symbolic action. A first action specified by the first policy rule is written into a corresponding action field of a corresponding MAT row in the output MAT template or the output MAT to replace the first symbolic action.

Abstract: Disclosed herein are heteroduplex nucleic acid molecules, heteroduplex nucleic acid conjugates, and pharmaceutical compositions for modulating a protein expression. Also described herein include methods of treating a disease or indication which utilize a heteroduplex nucleic acid molecule, a heteroduplex nucleic acid conjugate, or a pharmaceutical composition that comprises a heteroduplex nucleic acid molecule.